DK1651755T3 - Fremgangsmåde til immunterapi af tumorer - Google Patents
Fremgangsmåde til immunterapi af tumorerInfo
- Publication number
- DK1651755T3 DK1651755T3 DK04769204.1T DK04769204T DK1651755T3 DK 1651755 T3 DK1651755 T3 DK 1651755T3 DK 04769204 T DK04769204 T DK 04769204T DK 1651755 T3 DK1651755 T3 DK 1651755T3
- Authority
- DK
- Denmark
- Prior art keywords
- dendritic cells
- tumors
- immunotherapy
- antigen
- cells
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 238000009169 immunotherapy Methods 0.000 title 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102000002689 Toll-like receptor Human genes 0.000 abstract 1
- 108020000411 Toll-like receptor Proteins 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
- C12N2501/052—Lipopolysaccharides [LPS]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
- C12N2501/056—Immunostimulating oligonucleotides, e.g. CpG
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/185—Osteoprotegerin; Osteoclast differentiation factor (ODF, RANKL)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/52—CD40, CD40-ligand (CD154)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rehabilitation Therapy (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49198803P | 2003-08-04 | 2003-08-04 | |
PCT/IB2004/002788 WO2005012509A2 (en) | 2003-08-04 | 2004-08-04 | Method for immunotherapy of tumors |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1651755T3 true DK1651755T3 (da) | 2011-01-24 |
Family
ID=34115581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04769204.1T DK1651755T3 (da) | 2003-08-04 | 2004-08-04 | Fremgangsmåde til immunterapi af tumorer |
Country Status (13)
Country | Link |
---|---|
US (1) | US8124067B2 (da) |
EP (1) | EP1651755B1 (da) |
JP (1) | JP4939219B2 (da) |
CN (1) | CN1845988B (da) |
AT (1) | ATE484577T1 (da) |
AU (1) | AU2004261801B2 (da) |
CA (1) | CA2534377A1 (da) |
DE (1) | DE602004029578D1 (da) |
DK (1) | DK1651755T3 (da) |
ES (1) | ES2353964T3 (da) |
PL (1) | PL1651755T3 (da) |
PT (1) | PT1651755E (da) |
WO (1) | WO2005012509A2 (da) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080286312A1 (en) * | 2002-06-12 | 2008-11-20 | Gavish-Galilee Bio Applications Ltd. | Membrane-anchored beta2 microglobulincovalently linked to MHC class I peptide epitopes |
US7629135B2 (en) * | 2006-12-22 | 2009-12-08 | The Board Of Trustees Of The University Of Illinois | Toll-like receptor agonists and antagonists and methods of use thereof |
US9408909B2 (en) | 2007-09-14 | 2016-08-09 | Vrije Universiteit Brussel | Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination |
DK2201100T3 (da) * | 2007-09-14 | 2016-05-30 | Univ Bruxelles | Forbedring af t-cellestimulerende evne for humane antigenpræsenterende celler og anvendelse heraf i vaccination |
EP2201100B1 (en) * | 2007-09-14 | 2016-03-16 | Vrije Universiteit Brussel | Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination |
WO2009088401A2 (en) * | 2007-09-24 | 2009-07-16 | Government Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Immunostimulatory combinations of tlr ligands and methods of use |
WO2010068680A1 (en) | 2008-12-10 | 2010-06-17 | Mount Sinai School Of Medicine Of New York University | Thelper cell type 17 lineage-specific adjuvants, compositions and methods |
CN102803502B (zh) * | 2009-09-29 | 2019-06-04 | 宾夕法尼亚大学理事会 | 用于诊断和治疗脑炎或癫痫的方法 |
KR101365207B1 (ko) | 2011-12-06 | 2014-02-20 | 가톨릭대학교 산학협력단 | 마이오신을 이용하여 제조된 면역관용 수지상 세포 및 이의 제조 방법 |
KR101946572B1 (ko) * | 2017-01-31 | 2019-02-11 | 주식회사 큐라티스 | 면역 관용성 플라즈마사이토이드 수지상 세포 및 그 제조방법 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005501550A (ja) * | 2001-08-30 | 2005-01-20 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫反応調整剤分子を用いた形質細胞様樹状細胞を成熟させる方法 |
WO2003024480A2 (en) * | 2001-09-14 | 2003-03-27 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
-
2004
- 2004-08-04 AT AT04769204T patent/ATE484577T1/de active
- 2004-08-04 PL PL04769204T patent/PL1651755T3/pl unknown
- 2004-08-04 CN CN2004800250162A patent/CN1845988B/zh not_active Expired - Fee Related
- 2004-08-04 EP EP04769204A patent/EP1651755B1/en not_active Not-in-force
- 2004-08-04 PT PT04769204T patent/PT1651755E/pt unknown
- 2004-08-04 ES ES04769204T patent/ES2353964T3/es active Active
- 2004-08-04 AU AU2004261801A patent/AU2004261801B2/en not_active Ceased
- 2004-08-04 US US10/567,167 patent/US8124067B2/en not_active Expired - Fee Related
- 2004-08-04 JP JP2006522445A patent/JP4939219B2/ja not_active Expired - Fee Related
- 2004-08-04 DK DK04769204.1T patent/DK1651755T3/da active
- 2004-08-04 CA CA002534377A patent/CA2534377A1/en not_active Abandoned
- 2004-08-04 DE DE602004029578T patent/DE602004029578D1/de active Active
- 2004-08-04 WO PCT/IB2004/002788 patent/WO2005012509A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2005012509A3 (en) | 2005-04-21 |
US20060147427A1 (en) | 2006-07-06 |
AU2004261801A1 (en) | 2005-02-10 |
CA2534377A1 (en) | 2005-02-10 |
WO2005012509A2 (en) | 2005-02-10 |
AU2004261801B2 (en) | 2010-06-24 |
PT1651755E (pt) | 2011-01-18 |
ATE484577T1 (de) | 2010-10-15 |
JP4939219B2 (ja) | 2012-05-23 |
ES2353964T3 (es) | 2011-03-08 |
CN1845988A (zh) | 2006-10-11 |
EP1651755B1 (en) | 2010-10-13 |
EP1651755A2 (en) | 2006-05-03 |
DE602004029578D1 (de) | 2010-11-25 |
CN1845988B (zh) | 2011-09-14 |
US8124067B2 (en) | 2012-02-28 |
JP2007501607A (ja) | 2007-02-01 |
PL1651755T3 (pl) | 2011-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE554390T1 (de) | Verfahren zur gewinnung von antikörpern | |
SG166788A1 (en) | Use of b cell expansion agents in generating antibodies | |
ATE551367T1 (de) | Epha2-bindende antikörper und verfahren zu ihrer verwendung | |
DK1492440T3 (da) | Fremgangsmåde til opnåelse af en diagnose og prognose for maligne sygdomme | |
PH12016500658B1 (en) | Human anti-alpha-synuclein autoantibodies | |
DK1651755T3 (da) | Fremgangsmåde til immunterapi af tumorer | |
NO20084835L (no) | Dyrkingsmetode for a oppna en klonpopulasjon av antigen-spesifikke B celler | |
NO20054351L (no) | Monoklonalt antistoff og hybridom som produserer dette | |
DE602004018388D1 (de) | Proteinphosphorylierung bei grosszellig-anaplastischem lymphom | |
EA201000343A1 (ru) | ЧЛЕН СЕМЕЙСТВА B7, zB7H6 И РОДСТВЕННЫЕ КОМПОЗИЦИИ И СПОСОБЫ | |
ATE528648T1 (de) | Verfahren zum nachweis antikörper-herstellender zellen | |
PT1415158E (pt) | Metodo para seleccao de celulas que expressam anticorpos | |
CR9562A (es) | Anticuerpos anti-cd40 humanizados y sus metodos de uso | |
TW200801202A (en) | Alpha-enolase specific antibody and method of use | |
ATE505535T1 (de) | Verfahren zur herstellung stabiler b-lymphozyten | |
DE602007012836D1 (de) | Cd86- und cd80-rezeptorkonkurrenztests | |
WO2008052108A3 (en) | Methods for use in human-adapting monoclonal antibodies | |
DK1529216T3 (da) | Fremgangsmåde til diagnosticering af dissemineret sklerose | |
DE602005024254D1 (da) | ||
DK1711531T3 (da) | Neutraliserende anti-TLR4/-MD-2-antistoffer og fremgangsmåder til anvendelse deraf | |
DE602006010518D1 (de) | Verfahren zur Quantifizierung einer bestimmten Zellpopulation in einer menschlichen Blutprobe | |
WO2020064997A8 (en) | Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies in renal cell cancer | |
DE602004023238D1 (de) | Methoden zur Kultivierung von Antigen presentierenden Immunzellen | |
WO2010053772A3 (en) | Disease-associated antigens and methods of use thereof | |
DE602007003814D1 (de) | Immuntest für Tramadol und seine hauptsächlichen Metaboliten |